Homocysteine and venous thromboembolic disease: A new approach to venous thrombotic risk;Homocysteine et maladie thromboembolique veineuse: Une nouvelle approche du risque thrombotique veineux

Sang Thrombose Vaisseaux

Volumn 9, Issue 6, 1997, Pages 339-345

  Quéré, Isabelle ^a   Chassé, Jean François ^b   Janbon, Charles ^a  

^a HÔPITAL SAINT ELOI   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE;

DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; GENE MUTATION; GENETIC POLYMORPHISM; HOMOCYSTINURIA; HUMAN; HUMAN CELL; HUMAN TISSUE; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY; VEIN THROMBOSIS;

EID: 0030851712     PISSN: 09997385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (30)

1. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocysteine due to cystathionine-β synthase deficiency. Am J Human Genet 1985 ; 37: 1-31.
2. Aral B, CoudéM, Agarawa S, et al. Two novel mutations in the Cterminal moiety of the cystathionine-β synthase gene in two French pyridoxine-responsive homocystinuria patients. Hum Genef (in press).
3. Mandel H, Brenner B, Berant M, et al. Coexistence of hereditary homocystinuria and factor V Leiden effect on thrombosis. N Engl J Med 1996 ; 334: 763-8.
4. Quérél, Lamarti H, Chadefaux-Veckemans B. Thrombophilia, homocystinuria and mutation of the factor V gene. N Engl J Med 1996 ; 335: 289-90.
5. Brattström L, Tengborn L, Israelsson B, et al. Plasma homocysteine in venous thromboembolism. Haemostasis 1991 ; 21: 51-7.
6. Falcon CR, CattaneoM, Panzeri D, et al. Hyperhomocysteinemia in venous thrombosis. Arterioscler Thromb 1994 ; 14: 1080-3.
7. Fermol, Vigano 'D' Angelo S, Paroni R, et al. Prevalence of poderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med 1995 ; 123: 747-53.
8. Amundsen T, Ueland PM, Waage A. Plasma homocysteine in patients with deep venous thrombosis. Arterioscler Thromb Vasc Biol 1995 ; 15: 1321-3.
9. Den Heiger MD, BlomHJ, Gerrite WBJ, Rosendaal FR, Haak HL, Wijermans PW. Is hyperhomocysteinemia a risk factor for recurrent venous thrombosis? Lancet 1995 ; 345: 882-5.
10. Den Heiger MD, Koster T, Blom HJ Bos GMJ, Briët E, Reitsma PH, et al. Hyperhomocysteinemia a risk factor For deep-venous thrombosis. N Engl J Med 1996 ; 334: 759-62.
11. Simioni P, Prandoni P, Burlina A, et al. Hyperhomocysteinemia and deep venous thrombosis. A case-control study. Thromb Haemost 1996 ; 76: 883-6.
12. Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996 ; 348: 1120-4.
13. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus,reduces protein C activation by arterial and venous endothelial cells. Blood 1990 ; 75: 895-901.
14. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 1986 ; 77: 1909-16.
15. Hayashi T, Honda G, Suzuki K. An atherogenic stimulus, homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood 1992 ; 79: 2930-6.
16. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991 ;88: 1906-14.
17. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured procine aortic endothelial cells. J Clin Invest 1993 ; 92: 1381-6.
18. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator to cultured human endothelial cells. J Clin Invest 1993 ; 91 : 2873-9.
19. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb 1993 ; 13 : 1327-33.
20. Quéré I, Habib A, Tobelem G, Maclouf J. Inhibition of cyclooxygenase in human endothelial cells by homocysteine. Advances in prostaglandin, 4 thromboxane and leukotriene research 1995 ; 23 : 397-9.
21. Harpel PC, Chang VT, Borth W. Homocysteine and other sulfydryl compounds enhance the binding of lipoprotein(a) to fibrin : a potential biochemical link between thrombosis, atherogenesis and sulfhydryl compound metabolism. Proc Natl Acad Sci 1992 ; 89 : 10193-7.
22. Lentz SR, Sadler JE. Homocysteine inhibits von Willebrand factor processing and secretion by preventing transport from the endopiasmic reticulum. Blood 1993 ; 81 : 683-9.
23. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986 ;77 : 1370-6.
24. Verhoef P, Stampfer MJ, Buring JE, Gaziano JM, Allen RH, Stabler SP. Homocysteine metabolism and risk of myocardial infarction : relation with vitamins B6, B12 and folate. Am J Epidemiol 1996 ; 143 : 845-59.
25. Frosst P, Blom HJ, Milos R, Goyette P, Sheppart CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genetics 1995 ; 101 : 111-3.
26. Engbersen AMT, Franken DG, Boers GHJ, Stevens EMB, Triibels FJM, Blom HJ. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet 1995 ; 56 : 142-50
27. Kluijtmans LAJ, Van den Heuvel LPWJ, Blom HJ, Boers GHJ, Frosst P Stevens EMB, van OostBA, et al. Molecular genetic analysis in mild hyperhomocysteinemia : a common mutation in the MTHFR gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996 ; 58 : 35-41.
28. Quéré I, Dupuy E, Chadefaux-VeckemansB, Bellet H, Biron C, Kamoun P, Tobelem G, Janbon C. Homocysteine and deep vein thrombosis : C677T MTHFR genetic thermobbile variant and acid folic modulation of plasma homocysteine levels. Haemostasis 1996 ; 26 (suppl. 3): S188.
29. De Franchis R, Mancini FP, d'Angelo A, Sebastio G, Fermo l, de Stephano V. Elevated total plasma homocysteine and C677T mutation of the 5,10-methylenetetrahydrofolate reductase gene in thrombotic vascular disease. Am J Hum Genet 1996, 59 : 262-4.
30. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996 ; 93 : 7-0.